LEQVIO 284 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA

USDailyMed:Inclisiran AU:B1 C10AX16(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 1639324-58-5 DB14901 UOW2C71PG5 D11931 CHEBI:176399 Inclisiran, sold under the brand nameLeqvio, is amedicationused for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people withatherosclerotic cardiovascular disease(ASCVD), ASCVD risk-equivalents, andheterozygousfamilial hypercholesterolemia(HeFH).It is asmall interfering RNA(siRNA) that acts as aninhibitor of a proprotein convertase, specifically, inhibitingtranslationof the proteinPCSK9. Inclisiran was approved for use in the European Union in December 2020.In August 2021, it receivedNICEapproval for use by theNational Health Servicein the UK.In December 2021, it was approved for medical use in the United States.The U.S.Food and Drug Administrationconsiders it to be afirst-in-class medication.In August 2023, theNational Medical Products Administrationapproved the use of inclisiran in China.